Online citations, reference lists, and bibliographies.
← Back to Search

Botulinum Toxin Seroype A For Cervical Dystonia—An Assessment

A. Brashear
Published 2008 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Diagnosis of Cervical Dystonia Dystonia involves a lack of synergy of antagonist and agonist muscles, resulting in irregular and unco-ordinated movements. Clinically, focal dystonia occurs when the involuntary movements are isolated to one body part such as a limb (writer’s cramp), the larynx (spasmodic dysyphonia), or the eyes (blepharospasm). Cervical dystonia (CD), a form of focal dystonia involving the neck muscles, presents with abnormal postures of the neck. While typical CD presents with tilt (laterocollis), turn (torticollis), and/or pulling forward (anterocollis) or backward (retrocollis), any combination of these may be seen. In addition, some patients present with superimposed tremor and/or pain. While the involuntary movement is always part of CD presentation, in some patients pain can be the prominent complaint.
This paper references
Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency
K. Kessler (1999)
The safety and tolerability of botulinum toxins for the treatment of cervical dystonia
A. Brashear (2005)
Familial dopa-responsive cervical dystonia
S. Schneider (2006)
Development of resistance to botulinum toxin type A in patients with torticollis
P. Greene (1994)
CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia
S. Cano (2006)
Primate models of dystonia
D. Guehl (2009)
The prevalence of primary dystonia in the general community
J. Müller (2002)
Classification of dystonia.
S. Fahn (1998)
Botulinum toxin injections for cervical dystonia
J. Jankovic (1990)
Clinical Comparisons of Botulinum Neurotoxin Formulations
A. Brashear (2008)
Botulinum toxin treatment of occupational and focal hand dystonia
B. Karp (2004)
Clinico-immunologic aspects of botulinum toxin type B treatment of cervical dystonia
J. Jankovic (2006)
A new screening tool for cervical dystonia
R. Saunders-Pullman (2005)
Botulinum toxin versus trihexyphenidyl in cervical dystonia
J. Brans (1996)
Cervical dystonia
J. Jankovic (1991)
Quality of life in patients with focal dystonia
T. Pekmezović (2009)
The phenotypic spectrum of rapidonset dystoniaparkinsonism ( RDP ) and mutations in the ATP 1 A 3 gene
A Brashear (2007)
Safety and efficacy of NeuroBloc ( botulinum toxin type B ) in type Aresistant cervical dystonia
MF Brin (1999)
Safety and efficacy of NeuroBloc ( botulinum toxin type B ) in type Aresponsive cervical dystonia
A Brashear (1999)
Botulinum toxin injection for spasmodic torticollis
C. Comella (1992)
Minimum incidence of primary cervical dystonia in a multiethnic health care population
C. Marras (2007)
Botulinum toxin type B: a new injectable treatment for cervical dystonia
A. Brashear (2001)
Diagnostic criteria for dystonia in DYT1 families
S. Bressman (2002)
Cervical dystonia: clinical findings and associated movement disorders, Neurology, 1991;41:1088–91
J Jankovic (1991)
Comparison of acute‐ and delayed‐onset posttraumatic cervical dystonia
D. Tarsy (1998)
Utility of an EMG mapping study in treating cervical dystonia
J. V. van Gerpen (2000)
The botulinum toxins in the treatment of cervical dystonia.
A. Brashear (2001)
Myoclonus-dystonia, obsessive-compulsive disorder, and alcohol dependence in SGCE mutation carriers
C. W. Hess (2007)
The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene.
A. Brashear (2007)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
A. Brashear (1999)
The natural history of tardive dystonia. A long-term follow-up study of 107 cases.
V. Kiriakakis (1998)
Increased basal‐ganglia activation performing a non‐dystonia‐related task in focal dystonia
M. Obermann (2008)
Therapeutic Use of Botulinum Toxins: Background and History
P. Setler (2002)
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
Cervical dystonia severity scale reliability study
C. O'brien (2001)
Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review)
D. Simpson (2008)
What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport®
W. Poewe (1998)
Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double‐blind, placebo‐controlled study
D. Truong (2005)
Botulinum toxin type B versus type A in toxin-naive patients with cervical dystonia: Randomized, double-blind, non-inferiority trial, Mov Disord, 2008;23:510–17
EJ Pappert (2008)
Botulinum treatment of strabismus in children.
A. B. Scott (1989)
The diagnosis of dystonia
Howard L. Geyer (2006)
Capturing the true burden of dystonia on patients
S. Cano (2004)
Long‐term botulinum toxin treatment increases employment rate in patients with cervical dystonia
I. M. Skogseid (2005)
An open‐label trial of levetiracetam for treatment of cervical dystonia
D. Tarsy (2006)
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia, Neurology, 1999;53:1431–8
MF Brin (1999)
Comparison of treatment of tardive dystonia and idiopathic cervical dystonia with botulinum toxin type A
A. Brashear (1998)
Dose standardisation of botulinum toxin
EricR. First (1994)
Epidemiology of dystonia in Rochester, Minnesota.
J. Nutt (1988)
Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance, Neurology, 1992;42:878–82
CL Comella (1992)
Botulinum toxin injections for cervical dystonia, Neurology, 1990;40:277–80
J Jankovic (1990)
A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia
R. Benecke (2005)
Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
J. Slawek (2007)
An open trial of levetiracetam for segmental and generalized dystonia
S. Hering (2007)
What are the determinants of quality of life in people with cervical dystonia?
Y. Ben-Shlomo (2002)
Response and immunoresistance to botulinum toxin injections
J. Jankovic (1995)
Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: Randomized, double‐blind, noninferiority trial
E. Pappert (2008)
Long‐term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assay
M. Brin (2008)
Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia
C. Comella (2005)

This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar